MA-WASABI-TECHNOLOGIES
23.1.2024 15:01:31 CET | Business Wire | Press release
Wasabi Technologies, the hot cloud storage company, announces the acquisition of Curio AI from GrayMeta, Inc. Terms of the deal were not disclosed. The acquisition includes both the intellectual property and the visionary team behind Curio, including GrayMeta CEO Aaron Edell, who will join Wasabi as Senior Vice President of AI and Machine Learning. Wasabi will incorporate the Curio AI technology into a new class of AI-powered intelligent storage for the Media and Entertainment industry which it plans to release in Spring 2024.
Curio AI creates a second-by-second index of video stored in Wasabi. “A video archive without detailed metadata is like a library without a card catalog,” said David Friend, Chief Executive Officer, Wasabi Technologies. “This is where AI comes in. AI can find faces, logos, objects, and even specific voices. Without it, finding exactly the segments you are looking for requires tedious and time-consuming manual effort. The acquisition of Curio AI will allow us to revolutionize media storage.”
Video is one of the biggest opportunities in the storage industry. Hundreds of exabytes of video archives exist on aging tape systems, and many more exabytes are generated every year from film, television, sporting events, news, advertising, corporate communications, and countless hours of valuable raw footage and outtakes. Without searchable metadata, it’s extremely time consuming and inefficient to find video segments you need at any given moment.
Curio AI is an intelligent data platform that uses AI to generate rich metadata for media libraries and enables editors and producers to instantly search and retrieve specific media segments based on people, places, events, emotions, logos, landmarks, background audio and more. Curio AI can also detect and transcribe speech in over 50 spoken languages. Customers benefit from more personalized experiences with hyper specific detail, allowing organizations to deliver relevant content to market as fast as possible. Wasabi’s Curio AI-powered storage will provide customers like Liverpool Football Club with the metadata they need to manage troves of digital assets with lightning-fast speed.
“AI-powered storage will allow Wasabi customers to instantly find exactly what they need amongst millions of hours of footage and unleash the value in their archives. We believe this will be the most significant advance in the storage industry since the invention of object storage,” said Edell, Wasabi’s new Senior Vice President of AI and Machine Learning. “I look forward to working with Dave and the exceptional team he has built to write a new future for the media and entertainment industry.”
“Wasabi is on a trajectory that few others in the industry can claim. The advantage of being a hyper-focused company is that we can lead the industry in terms of price, performance, reliability, and innovation. With the acquisition of Curio AI, we are now set to introduce the industry’s first AI-powered intelligent cloud storage,” added Friend. “Like Wasabi’s standard cloud storage, our Curio AI-powered storage will be simple, fast, reliable, and inexpensive. With the acquisition of Curio AI, our customers will not only be able to store data but locate and instantly retrieve exactly what they want.”
About Wasabi Technologies
Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organizations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, while delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by customers worldwide, Wasabi has been recognized as one of technology’s fastest growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.
Follow and connect with Wasabi on LinkedIn, X, Facebook, Instagram, and The Bucket.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123706386/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom